Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10

Study acronym: DNF10-APET
StatusRecruiting
PhaseNot applicable
SponsorFytexia
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 2026 → Dec 2026
See other at-risk trials from Fytexia

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Dec 2026 Show 4 more changesShow less
    • Study completion pushed from Sep 2026 to Feb 2027
    • Interventions modified
    • Eligibility criteria expanded, about 29 words
    • Site details revised
  2. Primary endpoint(s) modifiedv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Fytexia
3 trials monitored
See 1 trial at risk
This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg/m². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.
Trial Details
NCT Number NCT07621393
Lead Sponsor Fytexia
Collaborators: Centros de Investigación de Nutrición y Salud
Conditions
(from sponsor)		 Healthy Adult
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov